Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (GB:0TDD)
LSE:0TDD
Novo Nordisk (0TDD) Share Price & Analysis
8 Followers
0TDD Stock Chart & Stats
Day’s Range$125.59 - $127.89
52-Week Range― - ―
Previous Close$124.51
Volume6.67K
Average Volume (3M)N/A
Market Cap
$564.00B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
$0.75Last Dividend Ex-Date
Mar 22, 2024Dividend Yield0.78%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$135.53Price Target Upside6.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Novo Nordisk News
PremiumCompany Announcements
Novo Nordisk Shares Capital and Voting Rights Update
PremiumCompany Announcements
Novo Nordisk Updates Corporate Governance Structure
PremiumCompany Announcements
Novo Nordisk Executes Share Capital Reduction
Bulls Say, Bears Say
Bulls Say
Manufacturing ExpansionExpanded manufacturing with Catalent enables Novo to supply the capacity-constrained market, potentially increasing its market share.
Market GrowthNovo is well positioned in the obesity market, with a strong pipeline that could drive growth in a market projected to exceed $130B.
Product PipelineNovo's in-development obesity and T2D assets are likely to expand their existing portfolio, strengthening their market position.
Bears Say
Acquisition ImpactThe acquisition is expected to have a low single-digit negative impact on operating profit growth in both 2024 and 2025.
Drug Sales PerformanceInsulin was a slight miss (-2%), with the most significant miss coming from the obesity portfolio (Wegovy -6%; Saxenda -34%).
Share Buyback And Capital ExpendituresThe planned share buyback is lower than expected due to higher capital expenditures, which could be a concern for investors looking for direct returns.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.88% Other Institutional Investors
99.12% Public Companies and
Individual Investors
0TDD FAQ
What was Novo Nordisk’s price range in the past 12 months?
Currently, no data Available
What is Novo Nordisk’s market cap?
Currently, no data Available
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 02, 2024 which is in 4 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Jan 31, 2024. The company reported $0.716 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.046.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.66 which represents an annual dividend yield of 0.78%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is $0.75.
How many shares outstanding does Novo Nordisk have?
Currently, no data Available
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.716 in its last earnings report, beating expectations of $0.67. Following the earnings report the stock price went up 3.81%.
Which hedge fund is a major shareholder of Novo Nordisk?
Among the largest hedge funds holding Novo Nordisk’s share is Fisher Asset Management LLC. It holds Novo Nordisk’s shares valued at 1B.
---
Novo Nordisk Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$135.53 (6.74% Upside)
$135.53 (6.74% Upside)
Blogger Sentiment
Bullish
GB:0TDD Sentiment 88%
Sector Average 70%
Sector Average 70%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.08%
12-Months-Change
Fundamentals
Return on Equity
87.44%
Trailing 12-Months
Asset Growth
34.59%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
0TDD Company Deck
---
0TDD Earnings Call
Q4 2024
0:00 / 0:00
---
0TDD Stock 12 Months Forecast
Average Price Target
$135.53
▲(6.74% Upside)
Technical Analysis
Best Analysts Covering 0TDD
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+25.64%
assigned a buy rating last month
Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +25.64% per trade.
---